Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC AUROBINDO PHARMA/
ALEMBIC
 
P/E (TTM) x 17.9 60.7 29.5% View Chart
P/BV x 3.9 5.2 74.0% View Chart
Dividend Yield % 0.3 0.2 139.4%  

Financials

 AUROBINDO PHARMA   ALEMBIC
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ALEMBIC
Mar-18
AUROBINDO PHARMA/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs83072 1,152.8%   
Low Rs52734 1,554.9%   
Sales per share (Unadj.) Rs333.94.7 7,103.4%  
Earnings per share (Unadj.) Rs40.46.1 661.2%  
Cash flow per share (Unadj.) Rs51.86.2 828.7%  
Dividends per share (Unadj.) Rs2.500.20 1,250.0%  
Dividend yield (eoy) %0.40.4 97.5%  
Book value per share (Unadj.) Rs237.140.7 583.1%  
Shares outstanding (eoy) m585.91267.03 219.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.011.3 18.0%   
Avg P/E ratio x16.88.7 193.8%  
P/CF ratio (eoy) x13.18.5 154.6%  
Price / Book Value ratio x2.91.3 219.8%  
Dividend payout %6.23.3 189.1%   
Avg Mkt Cap Rs m397,56914,139 2,811.8%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,849207 12,463.2%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,6361,255 15,586.0%  
Other income Rs m1,553370 419.6%   
Total revenues Rs m197,1891,625 12,131.7%   
Gross profit Rs m39,519111 35,571.0%  
Depreciation Rs m6,68038 17,670.6%   
Interest Rs m2,6262 154,470.6%   
Profit before tax Rs m31,767442 7,190.4%   
Minority Interest Rs m270-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,26924 30,348.6%   
Profit after tax Rs m23,6451,630 1,450.7%  
Gross profit margin %20.28.9 228.2%  
Effective tax rate %22.95.4 422.1%   
Net profit margin %12.1129.8 9.3%  
BALANCE SHEET DATA
Current assets Rs m153,6451,867 8,229.1%   
Current liabilities Rs m120,429591 20,370.3%   
Net working cap to sales %17.0101.6 16.7%  
Current ratio x1.33.2 40.4%  
Inventory Days Days13594 143.4%  
Debtors Days Days6474 86.6%  
Net fixed assets Rs m103,9091,791 5,802.0%   
Share capital Rs m586534 109.7%   
"Free" reserves Rs m138,32210,324 1,339.9%   
Net worth Rs m138,90810,858 1,279.3%   
Long term debt Rs m1,80041 4,367.7%   
Total assets Rs m264,54411,591 2,282.4%  
Interest coverage x13.1260.9 5.0%   
Debt to equity ratio x00 341.4%  
Sales to assets ratio x0.70.1 682.9%   
Return on assets %9.914.1 70.5%  
Return on equity %17.015.0 113.4%  
Return on capital %23.815.2 156.9%  
Exports to sales %49.61.5 3,211.0%   
Imports to sales %18.821.0 89.5%   
Exports (fob) Rs m97,09119 500,470.1%   
Imports (cif) Rs m36,741263 13,952.0%   
Fx inflow Rs m97,31619 501,630.9%   
Fx outflow Rs m40,589264 15,385.2%   
Net fx Rs m56,727-244 -23,208.9%   
CASH FLOW
From Operations Rs m16,220236 6,878.8%  
From Investments Rs m-28,768-224 12,843.0%  
From Financial Activity Rs m19,191-27 -72,145.1%  
Net Cashflow Rs m6,656-15 -44,975.7%  

Share Holding

Indian Promoters % 54.1 64.0 84.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 3,975.0%  
FIIs % 27.7 9.7 285.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.1 39.1%  
Shareholders   69,601 54,701 127.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 450 Points in Opening Trade; Mindtree Up 5% Post Q3 Results(09:30 am)

Asian share markets and US stock futures are trading higher today as investors awaited comments from Joe Biden's Treasury Secretary nominee Janet Yellen on US stimulus and the dollar.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 19, 2021 10:58 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS